News Adcendo raises $135m for cancer ADCs, and other financings Adcendo raises $135m for cancer ADCs, plus financings for Enveda, Cradle Bio, ATB Therapeutics, and 35Pharma
News Adcendo licenses Multitude anti-TF ADC in $1bn+ deal Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in variou
News ESC: MSD/Bayer's Verquvo disappoints in heart failure trial Bayer and MSD's hopes of expanding the use of Verquvo in heart failure have been dashed by a failed phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
